Urology Unit, Cannizzaro Hospital, Catania, Italy;
Urology Unit, Cannizzaro Hospital, Catania, Italy.
Anticancer Res. 2021 Jun;41(6):3127-3130. doi: 10.21873/anticanres.15097.
BACKGROUND/AIM: To evaluate the diagnosis and treatment of prostate cancer (PCa) during 1 year of the COVID-19 pandemic.
The management of men with PCa during COVID-19 pandemic (March 2020-2021) was compared with the clinical activity of the 12 months before the COVID-19 pandemic (March 2019-2020).
The number of clinical visits, prostate biopsy, and men enrolled in active surveillance was significantly lower during the COVID-19 pandemic (p<0.05); on the contrary, the number of cases with advanced (pT3b: 11.2 vs. 25.6%; nodal positive: 14.8 vs. 46.1%) and metastatic (5.9 vs. 9.3%) PCa increased. The number of open radical prostatectomies increased compared with the ones using a laparoscopic approach; moreover, more men were treated with external radiotherapy (25.1 vs. 54.2%).
The guideline recommendations in the management of PCa should constantly adapt to the epidemiological evolution, but the overall cost of delayed diagnosis will increase in the near future.
背景/目的:评估 COVID-19 大流行期间前列腺癌(PCa)的诊断和治疗情况。
比较了 COVID-19 大流行期间(2020 年 3 月至 2021 年)男性 PCa 的治疗管理与 COVID-19 大流行前 12 个月(2019 年 3 月至 2020 年)的临床活动。
COVID-19 大流行期间临床就诊、前列腺活检和接受主动监测的男性数量明显减少(p<0.05);相反,晚期(pT3b:11.2%比 25.6%;淋巴结阳性:14.8%比 46.1%)和转移性(5.9%比 9.3%)PCa 病例数量增加。与腹腔镜方法相比,开放性根治性前列腺切除术的数量增加;此外,更多的男性接受了外部放射治疗(25.1%比 54.2%)。
PCa 管理中的指南建议应不断适应流行病学的演变,但未来不久,延迟诊断的总体成本将会增加。